SITM:NASDAQSiTime Corporation Analysis
Data as of 2026-05-01 - not real-time
$562.15
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
SiTime’s stock is trading well above its 20‑day (474), 50‑day (407) and 200‑day (325) moving averages, confirming a strong bullish technical backdrop, while the RSI of 70.4 signals an overbought condition. The MACD line sits above its signal line, producing a bullish histogram, and volume is on an upward trend, all of which support short‑term upward momentum.
However, the forward P/E of 84.3 dwarfs the industry average of 37.9, and a discounted cash‑flow fair‑value of $47.8 is starkly lower than the current price of $562, indicating that the market is pricing in a substantial premium. The company’s revenue surged 66% year‑over‑year with a solid 53.6% gross margin, yet operating and net margins remain negative, and EBITDA is in the red. A robust cash pile of $808 M versus minimal debt (Debt/Equity 0.31) provides liquidity, but high beta (2.56) and 30‑day volatility of 71% amplify price risk. The recent $1.5 B acquisition of Renesas’ timing business is a pivotal catalyst that could unlock new markets, but integration risk remains. Analyst consensus leans heavily bullish (strong‑buy) despite a median price target of $450, well below today’s level, underscoring the overvaluation concerns.
However, the forward P/E of 84.3 dwarfs the industry average of 37.9, and a discounted cash‑flow fair‑value of $47.8 is starkly lower than the current price of $562, indicating that the market is pricing in a substantial premium. The company’s revenue surged 66% year‑over‑year with a solid 53.6% gross margin, yet operating and net margins remain negative, and EBITDA is in the red. A robust cash pile of $808 M versus minimal debt (Debt/Equity 0.31) provides liquidity, but high beta (2.56) and 30‑day volatility of 71% amplify price risk. The recent $1.5 B acquisition of Renesas’ timing business is a pivotal catalyst that could unlock new markets, but integration risk remains. Analyst consensus leans heavily bullish (strong‑buy) despite a median price target of $450, well below today’s level, underscoring the overvaluation concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Overbought RSI and price well above fair‑value DCF
- Bullish technical momentum but elevated volatility
- Upcoming Q1 2026 earnings could trigger price correction
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Renesas acquisition provides strategic growth and market expansion
- Strong revenue growth and high gross margins
- Ample cash reserves to fund integration and R&D
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Positioning in AI, data‑center and IoT timing markets
- Potential for margin improvement as integration matures
- Low debt and sustainable cash flow generation
Key Metrics & Analysis
Financial Health
Revenue Growth66.30%
Profit Margin-13.13%
P/E Ratio84.3
ROE-4.62%
ROA-3.57%
Debt/Equity0.31
P/B Ratio12.8
Op. Cash Flow$87.2M
Free Cash Flow$12.6M
Industry P/E37.9
Technical Analysis
TrendBullish
RSI70.4
Support$330.13
Resistance$591.13
MA 20$474.07
MA 50$407.33
MA 200$325.33
MACDBullish
VolumeIncreasing
Fear & Greed Index90.88
Valuation
Fair Value$47.82
Target Price$495.56
Upside/Downside-11.85%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.56
Volatility71.53%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.